Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence.
about
Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyEscherichia coli and selected veterinary and zoonotic pathogens isolated from environmental sites in companion animal veterinary hospitals in southern Ontario.Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data.Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review.Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis.Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringensDetermining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods.Development of hemiacetal esterified levofloxacin to prevent chelation with metal-containing drugs.Antibiotic-associated diarrhea: epidemiology, trends and treatment.Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015.Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1.Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.The continually evolving Clostridium difficile species.Levofloxacin for the treatment of pyelonephritis.Dual-coated lactic acid bacteria: an emerging innovative technology in the field of probiotics.Should quinolones come first in Helicobacter pylori therapy?Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.Clostridium difficile-associated diarrhea in a tertiary care medical center.Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection.Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
P2860
Q26824268-645869E3-28A2-45D1-B2BA-5B1E85A26FBAQ27692069-903BC4EF-07F8-4A41-91C4-EE2379CEEF4EQ31105341-01D5A6DD-D45E-43DE-A119-D1C8040A2838Q34137328-49F99196-D171-4D87-BB06-8FF4A2A21F64Q34213457-0401AADD-FCF6-47BE-B4C5-6D58A5F99BC1Q34604406-F1144818-BC16-4078-A1E1-DE136F2139ADQ35617258-92EA4C89-F780-4FA3-87F8-F1B07DBDA933Q36172700-48E80767-E345-43C1-B185-AF9F1C0392A9Q37277087-7715C185-31A0-4B06-B24B-51A339388B23Q37333929-E365C307-97C1-4706-B447-E36268EF9E0CQ37451064-BDFF2060-E282-4F47-89F5-600993F9B571Q37543222-A57BC537-9BF2-4DBD-B72E-B60F0EAC2CE0Q38036704-999A9D69-C768-4EF8-A9F5-2B1AF0903A1AQ38101380-A03D8918-38D9-44D5-871E-3C8DDD2A191DQ38700972-C90B3B0A-D01B-4449-A8FB-8D06D8A65F06Q41807465-D31CD97B-B1BB-49C8-9F24-FC5A7AF3B1A2Q42116391-CAC80D6B-AAEE-47F9-B1E3-0002BD1765ABQ42423715-1233EC22-B316-4A71-AA84-487E316CE489Q44663435-72979436-CF50-489A-B91A-170310AD436EQ44982093-5CB65BE5-410D-470F-8791-A4FF678EF761
P2860
Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@ast
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@en
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@nl
type
label
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@ast
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@en
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@nl
prefLabel
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@ast
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@en
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@nl
P2093
P356
P1476
Do fluoroquinolones predispose ...... ase? A review of the evidence.
@en
P2093
Abhishek Deshpande
Chaitanya Pant
David D K Rolston
Thomas G Fraser
P304
P356
10.1185/030079908X253735
P407
P577
2008-02-01T00:00:00Z